Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day ☆ , ☆☆ Most atypical antipsychotic drugs (APDs), e.g. risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT) 2A than dopamine (DA) D 2 receptors. This distinguishes them from typical APDs, e.g. haloperidol (HAL). Our objective was to test the hypothesis that augmentation of low doses of RIS or HAL (2 mg/day) with pimavanserin (PIM), a selective 5-HT 2A inverse agonist, to enhance 5-HT 2A receptor blockade, can achieve efficacy comparable to RIS, 6 mg/day, but with lesser side effects. In a multi-center, randomized, double-blind, 6 week trial, 423 patients with chronic schizophrenia experiencing a recent exacerbation of psychotic symptoms were randomized to RIS2mg + placebo (RIS2PBO), RIS2mg + PIM20mg (RIS2PIM), RIS6mg + PBO (RIS6PBO), HAL2mg + PBO (HAL2PBO), or HAL2mg + PIM20mg (HAL2PIM). Improvement in psychopathology was measured by the PANSS and CGI-S. The reduction in PANSS Total Score with RIS2PIM at endpoint was significantly greater than RIS2PBO: − 23.0 vs. − 16.3 (p = 0.007), and not significantly different from the RIS6PBO group: − 23.2 points. The percentage of patients with ≥ 20% improvement at day 15 in the RIS2PIM group was 62.3%, significantly greater than the RIS6PBO (42.1%; p = 0.01) and the RIS2PBO groups (37.7%; p = 0.002). Weight gain and hyperprolactinemia were greater in the RIS6PBO group than the RIS2PIM group but there was no difference in extrapyramidal side effects (EPS). HAL2PBO and HAL2PIM were not significantly different from each other in efficacy but HAL2PIM had less EPS at end point. Both HAL groups and RIS6PBO showed equal improvement in psychopathology at endpoint, indicating HAL 2 mg/day is effective to treat an acute exacerbation in chronic schizophrenia patients. In conclusion, a sub-effective RIS dose combined with PIM to enhance 5-HT 2A receptor blockade provided faster onset of action, and at endpoint, equal efficacy and better safety, compared to standard dose RIS. These results support the conclusion that 5-HT 2A receptor blockade is a key component of the action of some atypical APDs and can reduce EPS due to a typical APD.
Introduction
Schizophrenia is characterized by positive and negative symptoms, cognitive impairment and major deficits in social and work function (Buchanan, 2007; Harvey and Bellack, 2009; Kalkstein et al., 2010; Keshavan et al., 2011) . Antipsychotic drugs (APDs) are classified as 'typical' or 'atypical' based on their liability to cause extrapyramidal symptoms (EPS) at clinically effective doses (Meltzer, 2000) . Both classes of drugs treat positive symptoms in approximately 70% of patients with non-treatment resistant schizophrenia (Leucht et al., 2000; Lieberman et al., 2005; Meltzer and Bobo, 2006) . Metabolic side effects, e.g. weight gain, hyperlipidemia, and type II diabetes mellitus, are the principal risks associated with some atypical APDs (Morrato et al., 2009; Meltzer et al., 2011a) , while tardive dyskinesia, which is associated with increased mortality, cognitive impairment, and other adverse consequences, is much more common and severe with typical APDs (Byne et al., 1998; Margolese et al., 2005; Dean and Thuras, 2009) . Thus, side effect minimization is or should be a central consideration in choice of APDs (Velligan et al., 2009) .
There is extensive preclinical and clinical evidence that 5-HT 2A receptor antagonism contributes to the efficacy and reduced motoric side effects of some atypical APDs (Meltzer et al., 1989 (Meltzer et al., , 2012 Ichikawa et al., 2002; Weiner et al., 2003; Li et al., 2004; Meltzer and Huang, 2008) , although this has been disputed (Kapur and Seeman, 2001) . 5-HT 2A receptors are strategically located on glutamatergic, GABAergic, cholinergic, serotonergic and dopaminergic neurons where they are generally excitatory (Nocjar et al., 2002; Lüttgen et al., 2005; Meltzer and Huang, 2008) . The atypical APDs vary greatly in their affinities for other receptors which affect a wide range of brain functions, e.g. DA D 1 , 5-HT 2C , 5-HT 6 , 5-HT 7 , muscarinic, α 1 -and α 2 -adrenergic and H 1 -receptors. Some, but not all, of these receptor-mediated effects contribute to their efficacy and tolerability (Schotte et al., 1996; Kroeze et al., 2003; Meltzer and Huang, 2008; Meltzer et al., 2012) . The shared pharmacology of typical APDs is limited to D 2 receptor antagonism (Creese et al., 1976) which predicts efficacy and mechanism-driven side effects such as EPS and plasma prolactin increases. Selective 5-HT 2A inverse agonists such as SR43460B and M100907 produce greater improvement than placebo in some measures of psychopathology in acutely psychotic patients with schizophrenia, one of many indications of the potential beneficial contribution of 5-HT 2A receptor blockade to the efficacy of those APDs which achieve 5-HT 2A receptor blockade in vivo Snigdha et al., 2010; Preda et al., 2011) . Ritanserin, a mixed 5-HT 2A/2C antagonist (Schreiber et al., 1994) , was reported to improve positive and negative symptoms in a four week trial in 10 acutely psychotic patients with schizophrenia (Wiesel et al., 1994) . The combination of ritanserin and RIS6mg/day in a placebo-controlled trial in chronic schizophrenia patients with prominent negative symptoms showed significantly greater improvement in negative symptoms between weeks 6 and 8, but not at earlier periods. There was no difference between the two groups with regard to improvement in positive symptoms or general psychopathology (Akhondzadeh et al., 2008) .
Pimavanserin (PIM), another selective 5-HT 2A inverse agonist (Vanover et al., 2006) , has been reported to reduce delusions and hallucinations in a placebo-controlled trial in patients with Parkinson's disease psychosis (Meltzer et al., 2010b) . PIM has been shown to enhance the efficacy in rats of HAL to inhibit amphetamine-induced hyperactivity. PIM also synergistically interacted with HAL and RIS to suppress hyperactivity induced by the N-methyl-d-aspartate receptor antagonist (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine hydrogen maleate (MK-801). These are two accepted models of antipsychotic activity. Furthermore, PIM attenuated HAL-and RIS-induced catalepsy and hyperprolactinemia (Gardell et al., 2007) . PIM was more effective to potentiate RIS than HAL with regard to attenuation of catalepsy.
On the basis of these considerations, we tested the hypothesis that the addition of PIM to what was predicted to be sub-effective doses of the atypical APD, risperidone (RIS), or the typical APD, haloperidol (HAL), (McEvoy et al., 1986 (McEvoy et al., , 1991 Marder and Meibach, 1994) , would lead to clinical efficacy comparable to that of RIS, 6 mg/day, a dose believed to be effective in the majority of non-treatment resistant schizophrenia patients, and at the same time, produce less severe weight gain, EPS, and serum prolactin elevations (Nyberg et al., 1995 (Nyberg et al., , 1999 Lieberman et al., 2005) . Based on PET data (Nordstrom et al., 2008) , a 20 mg dose of PIM was chosen to ensure maximal occupancy of the brain 5-HT 2A receptors.
Thus, the current study investigated the effect of co-therapy with PIM (20 mg QD) and a presumptive suboptimal dose of RIS (1 mg BID; RIS2PIM) or HAL (2 mg QD; HAL2PIM) as representatives of atypical and typical APDs, respectively, in patients with chronic schizophrenia experiencing an acute exacerbation of psychotic symptoms. Explorative objectives were to compare both RIS2PIM and HAL2PIM to RIS6PBO in terms of efficacy and safety.
Methods

Study design
None-first episode patients who met DSM-IV criteria for schizophrenia experiencing a recent exacerbation of psychotic symptoms were recruited from 11 sites in the United States (n = 240) and seven in Brazil (n = 183) for this randomized, multicenter, doubleblind, six week trial to test the effectiveness and safety of combining PIM with suboptimal doses of RIS and HAL. The sample size was based upon a power analysis. The protocol was approved by the appropriate institutional review boards in both countries. Written informed consent was obtained from each patient following a full explanation of study procedures, risks and benefits. Raters were trained and qualified for PANSS assessment. The study was conducted according to globally accepted standards of good clinical practice (as defined in the International Conference on Harmonisation [ICH] E6 Guideline for Good Clinical Practice [GCP], 1 May 1996), in agreement with the latest revision of the Declaration of Helsinki regulations.
Patients were enrolled over a 14 month period. Following a 2-to 14-day screening period, eligible patients were randomized to one of five treatment arms:1) RIS6mg (3 mg BID) plus placebo (RIS6PBO); 2) RIS2mg (1 mg BID) plus placebo (RIS2PBO); 3) RIS2mg (1 mg BID) plus PIM20mg (RIS2PIM); 4) HAL2mg plus PIM20mg (HAL2PIM); and 5) HAL2mg plus placebo (HAL2PBO), and treated on an in-patient and subsequently out-patient basis for up to 6 weeks. All current psychotropic medications were discontinued at randomization.
The primary objective of this study was to determine if RIS2PIM or HAL2PIM would demonstrate antipsychotic efficacy superior to that of RIS2PBO or HAL2PBO, respectively. Secondary objectives were to: 1) determine whether RIS2PIM or HAL2PIM would demonstrate efficacy against negative symptoms when compared with RIS2PBO or HAL2PBO, respectively; and 2) assess the safety and tolerability of RIS2PIM and HAL2PIM in schizophrenia subjects. Exploratory objectives were to compare the RIS2PIM and HAL2PIM combinations to RIS6PBO (standard treatment) with regard to efficacy and safety.
Patient selection
Men or women 18 to 65 years old who met DSM-IV criteria for schizophrenia, with a recent acute exacerbation of psychotic symptoms, a history of ≥ two episodes, and who were not considered to be treatment resistant were eligible to participate in the study. A baseline Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) score ≥ 65 and a score of four or more on two of the four PANSS positive symptom items: delusions, hallucinatory behavior, conceptual disorganization, or suspiciousness, with at least one of the two items being delusions or hallucinatory behavior.
Assessments
The changes in PANSS total Score was the primary efficacy measure. Change in PANSS Positive, Negative and General Psychopathology symptom subscale scores, the Clinical Global Impression-Severity (CGI-S) (Guy, 1976) , to measure clinical severity, and the Calgary Depression Scale for Schizophrenia (CDSS), to assess depression (Addington et al., 1990) were secondary outcome measures. The three scales were performed at Baseline (day −1) and then two to six hours post-dose at visits at day 8, day 15, day 22, day 29, day 36 and day 43. The Barnes Akathisia Scale (BAS; Barnes, 1989 ) and the Simpson-Angus Scale (SAS; Simpson and Angus, 1970) were administered at baseline and six to nine hours after dosing on day 1 and each of the study visit days listed above. Safety was assessed by comparing adverse events along with changes from baseline in weight, laboratory values (including prolactin), ECGs, vital signs, and physical examinations (including a brief neurological exam) on day 15 and 43.
Data analysis
Sample size for this study was based on a minimum of 80% power to detect a difference of 5 points between the group receiving RIS2PIM and the RIS2PBO group in the mean change from baseline to day 43 in PANSS total score, with the assumption of a within group standard deviation of 10 points and a two-sided test at the 5% significance level. A sample size of at least 80 patients per group was therefore required.
The primary efficacy variable and each of the secondary efficacy variables were summarized by visit using descriptive statistics for continuous data, and using frequency counts and percentages for categorical data. For each of the secondary efficacy variables, the following treatment group comparisons were investigated: RIS2PBO vs. RIS2PIM and HAL2PBO vs. HAL2PIM. These groups were also compared with RIS6PBO.
As stated in the statistical plan, the primary efficacy measure was change from baseline to day 43 (endpoint) in mean PANSS total score using the ITT LOCF population for RIS2PIM and HAL2PIM. For the continuous secondary efficacy endpoints, differences between the treatment groups were assessed for mean change from baseline to each visit using an analysis of covariance (ANCOVA) with baseline score as covariate, and inclusion of treatment, country, and treatment by country interaction in the model. The treatment by country effect was tested at an alpha level of 0.10 for the homogeneity of treatment effect between the two countries. Although treatment comparisons were made at each visit for the ITT (observed cases [OC] and last observation carried forward [LOCF] ) and per protocol (OC and LOCF) populations, the primary analysis was the ITT LOCF at day 43. Each treatment group comparison was tested at an alpha level of 0.05. For the categorical secondary efficacy endpoints, differences between treatment groups were assessed at each visit for the ITT (OC and LOCF) and per protocol (OC and LOCF) populations, using the Cochran Mantel-Haenszel test stratified by country. The primary analysis was the ITT LOCF at day 43. Exploratory efficacy analyses were also performed.
Determination of plasma levels
PIM, HAL, RIS, and 9-OHRIS levels were determined at days 15 and 43, using high pressure liquid chromatography by Tandem Labs, 1121 East 3900 South, Salt Lake City, UT 84124. The plasma levels of PIM, HAL, RIS, 9-OHRIS, combined RIS and 9-OHRIS, as well as RIS/9-OHRIS ratios, were summarized using descriptive statistics for each scheduled sampling time for all study days by treatment. The effect of PIM on the RIS and HAL measures was compared by t-test.
Results
The descriptive and demographic data for the five groups of patients are given in Table 1 . There were no statistically significant differences in age, sex, race, BMI, proportion hospitalized at baseline, all baseline PANSS measures, or CGI, among the five patient groups. Fig. 1 provides the patient flow diagram. Of the 607 patients screened, 184 (30.3%) were screen failures, leaving 423 patients (69.7%) who were randomized to five treatment groups.
RIS2PBO vs RIS2PIM and other treatments
The changes in PANSS Total score for the five groups between baseline and subsequent visits are given in Fig. 2a .The changes in PANSS Positive, Negative, General and Cognitive scores are given in Table 2 . The primary efficacy measure, change from baseline to day 43 (endpoint) in mean PANSS total score (ITT LOCF) between groups, was statistically significant (p b 0.0001). The RIS2PIM group achieved a 23.0-point mean reduction (27.4%) in PANSS total score from baseline, at day 43, compared to a 16.3 point mean reduction (18.6%) in PANSS total score in the RIS2PBO group, significantly less than that of the RIS2PIM group (p = 0.007). Furthermore, the RIS2PIM group also had statistically significantly greater improvements compared to the RIS2PBO group for PANSS total score and all its subscales, at all visits after day 8 (Table 2 and Fig. 2 ). The improvements in the PANSS negative symptom (p = 0.018), and general psychopathology scores (p = 0.006) at end point were significantly greater in the RIS2PIM compared to the RIS2PBO group. There was a trend for a similar advantage for improvement in PANSS positive symptom scale score (p = 0.058) at day 43 (Table 1 ). The all-cause discontinuation rate in the RIS2PBO group (50%) as well as that for lack of efficacy (17.9%; both p = 0.05) were significantly greater than those for the RIS2PIM group, as well as those of any for any of the other treatment groups.
The improvement in PANSS total score at endpoint was also analyzed based on categorical improvement (≥20% and ≥50%) from baseline. Ad-hoc analyses using ≥30% and ≥ 40% PANSS improvement from baseline were also performed. The RIS2PBO and RIS2PIM rates were significantly different, favoring RIS2PIM, at day 43 based upon ≥ 20% (p = 0.001), ≥ 40% (p = 0.049), and ≥50% (p = 0.039) PANSS improvement criteria. Importantly, the proportions of subjects meeting these response criteria at endpoint for the RIS2PIM and the RIS6PBO group for the ITT LOCF sample were not statistically significantly different for any of the percentage-improvement levels.
Early response in the RIS2PIM treatment group compared to other RIS treatment groups
For the ≥ 20% PANSS improvement analysis, the improvement in the RIS2PIM group was significantly greater at week 2 (day 15) versus the RIS2PBO (p = 0.002; Fig. 2b ). Fifty (72.5 %) of the 69 RIS2PIM subjects met this response criterion by day 43, of whom 31 (62.0%) did so by two weeks. On the other hand, of the 48 (63.2%) of 76 patients who responded to RIS6PBO by day 43, only 20 (41.7%) responded by two weeks. Thus, response was significantly more rapid with RIS2PIM compared to RIS6PBO (p = 0.01) group.
Mean CGI-S scores (Fig. 2c ) significantly improved from baseline to day 43 in the RIS2PIM group (−1.3 points) compared with the RIS2PBO group (− 0.9 points, p = 0.008). The greater improvement in CGI was observed as early as day 15 (p = 0.006) and continued to endpoint (day 22, p = 0.003, day 29, p = 0.003, day 36, p = 0.002).
Comparison of change in PANSS scores for all treatment groups
The decrease in PANSS total score from baseline in the RIS6PBO, HAL2PIM and HAL2PBO groups were not significantly different from each other or from the RIS2PIM group at endpoint (Table 2, Fig. 2 ). The improvements from baseline to day 43 in the RIS2PIM group (− 23.0), the RIS6PBO group (− 23.2), the HAL2PIM (− 21.8), and the HAL2PBO (− 25.1) groups were essentially identical. It is highly noteworthy that the improvement in PANSS total score from baseline of the RIS2PIM group was not significantly different from that of the RIS6PBO group at any visit. However, the more rapid response of the RIS2PIM compared to the RIS6PBO groups was suggested by the general psychopathology subscale comparison which was close to significant in favor of RIS2PIM versus RIS6PBO at days 15 (p = 0.07) and 22 (p= 0.07). The mean change from baseline in CGI-S scores was not significantly different for the RIS2PIM and the RIS6PBO groups.
Efficacy of HAL2PIM and HAL2PBO
PANSS total scores were similarly reduced from baseline to endpoint in the HAL2PIM (− 21.8 points, 25.5%) subjects and those treated with HAL2PBO (− 25.1 points, 29.0%, p = 0.24), respectively. In contrast with the results of augmentation of RIS2mg with PIM, there was no significant difference in the improvement in PANSS negative subscale score between HAL2PIM and HAL2PBO. An exploratory analysis assessing PANSS total score change from baseline in the HAL2PIM and RIS6PBO groups showed that both produced similar reductions from baseline to endpoint (− 21.8 A PANSS responder analysis indicated that, at day 43, 63.6% of both the HAL2PIM and the HAL2PBO groups achieved at least a 20% reduction in PANSS total score. Analysis of CGI-S scores demonstrated similar mean reductions from baseline to endpoint for subjects treated with HAL2PIM (−1.2 points), HAL2PBO (−1.4 points) and RIS6PBO (−1.2 points), respectively. It is noteworthy that HAL2PBO was as effective as RIS6PBO with regard to all efficacy measures, indicating that even patients with an acute exacerbation of chronic schizophrenia are responsive to this low dose of HAL.
Plasma levels of RIS, HAL, and PIM
The mean trough plasma levels of HAL, RIS, 9-OHRIS, the RIS/ 9-OHRIS ratio, and PIM levels at days 15 and 43 are given in Tables 3A  and 3B . There were no significant differences in RIS or 9-OHRIS levels or their ratios in the RIS2PBO and RIS2 PIM groups at days 15 or 43. The RIS and 9-OHRIS levels in the RIS6PB0 groups compared to the average of the two RIS2 groups were 2.5-and 1.7-fold higher at days 15 and 43, respectively. Thus, co-administration of PIM20mg with either HAL or RIS did not affect trough HAL, RIS, 9-OHRIS, or combined RIS plasma concentrations. Similarly, PIM trough concentrations at day 15 or day 43 were not significantly different in the HAL2PIM and RIS2PIM groups (Tables 3A and 3B ). Plasma HAL levels at day 43 in those with ≥20% improvement in PANSS Total, with or without PIM augmentation, were not significantly different (data not presented).
Tolerability
As shown in Table 4 , there were no significant differences in motoric tolerability (BAS, SAS) between RIS2PIM, RIS2PBO, and RIS6PBO. Analysis of the subset of subjects who entered the study with a BAS score of 0 showed less increase in akathisia with RIS2PIM than RIS2PBO (0.3 vs. 0.9; p = 0.052) at day 43. The HAL2PIM group produced a decrease of 0.6 points in mean SAS score at day 43 compared to a decrease of 0.3 points for the HAL2PBO group (p = 0.07). A comparison to the RIS6PBO group (mean SAS decrease of 0.2 points) also favored the HAL2PIM group (p = 0.06).
General safety
Treatment-emergent adverse events (TEAEs) were similar among all treatment groups. The most frequently reported TEAEs were headache, sedation, nausea, and agitation. Of TEAEs in either PIM co-therapy group, compared with their respective placebo group(s), only somnolence, nausea and, to a lesser extent, dyspepsia, diarrhea, and pain in an extremity had a higher incidence (> 2 percentage point difference) in both co-therapy groups. The incidence of agitation was greatest in the RIS2PIM group (25.3%) but no subject in either co-therapy group discontinued treatment due to agitation. No lifethreatening TEAEs or deaths were reported in either co-therapy group. The most frequent TEAEs leading to discontinuation were psychiatric, neurological, or gastrointestinal disorders. These did not differ in frequency in the five groups. There were 25 serious adverse events (SAEs) in 23 subjects. Four subjects each in the RIS2PIM (5.1%) and the HAL2PIM group (4.9%) reported SAEs. In comparison, eight (9.6%) subjects in the RIS2PBO group, five (5.9%) subjects in the RIS6PBO group, and two (2.4%) subjects in the HAL2PBO group reported SAEs. Weight gain was notably higher in the RIS6PBO group compared to both co-therapy groups (Fig. 3a) . Mean weight gain from the screening visit to the final visit was 2.11 kg in the RIS6PBO group compared with 1.07 kg in the RIS2PIM group (p =0.05),1.05 kg in the RIS2PBO group, 0.44 kg in the HAL2PIM group, and 0.77 kg in the HAL2PBO group. The percentage of subjects who gained at least 7% in weight at endpoint was significantly greater in the RIS6PBO (18.9%) compared with the RIS2PIM group (6.3%; p=0.03). There was no difference in weight gain between the HAL2PIM and HAL2PBO groups. Increases in serum glucose and prolactin levels were notably higher in the RIS6PBO group compared to the RIS2PIM or the HAL2PIM groups (Fig. 3b and c) . In a ranked analysis of covariance comparison, the change in prolactin levels from baseline was significantly greater at day 43 in the RIS6PBO compared to the RIS2PIM (p = 0.0004) and HAL2PIM (p b 0.0001) groups. Similarly, mean serum glucose levels increased significantly more in the RIP6PBO (0.56 mmol/L) than in the RIS2PIM (0.20 mmol/L) group at endpoint (p = 0.02). The mean serum glucose increase at endpoint in the HAL2PIM group was 0.28 mmol/L. Additionally, shifts from normal (baseline) to high (endpoint) in SPTT, creatine kinase, SGOT/AST, and SGPT/ALT were fewer in the co-therapy arms versus the RIS6PBO group. Normal to high shifts in triglycerides, HDL cholesterol, LDL cholesterol, and total cholesterol were variable and inconsistent among treatment groups, as were shifts in bilirubin measures. There were no laboratory, vital sign, or ECG findings producing safety concerns in the PIM-treated groups.
Discussion
The principal aim of this study was to determine if a selective 5-HT 2A inverse agonist, PIM, could restore the efficacy of low, sub-effective doses of representative atypical and typical APDs, in acutely psychotic chronic schizophrenia patients, along with advantages for side effects such as weight gain and EPS as the result of the lower doses of the APDs. With PIM augmentation, RIS2mg had efficacy comparable to RIS6PBO at 6 weeks and, importantly, was found to be more effective at day 15. PIM augmentation also potentiated the improvement in negative symptoms produced by RIS2mg. As predicted, RIS2PIM produced significantly fewer motor and metabolic side effects than RIS6PBO at endpoint. Unexpectedly, HAL2PBO was as effective as RIS6PBO and HAL2PIM at all time points. PIM did not potentiate the efficacy of HAL on any aspect of psychopathology. However, there was some evidence that PIM augmentation reduced akathisia and other EPS produced by HAL2mg. There was no evidence that pharmacokinetic differences contributed to these findings, as PIM did not influence the levels of RIS, 9-OHRIS, the major metabolite of RIS, the RIS/9-OHRIS ratio, or HAL levels in plasma.
We compared RIS 6 mg/day, considered the standard RIS dose, and PBO with what were expected to be sub-effective doses of RIS and HAL, 2 mg/day (Chouinard et al., 1993; Marder and Meibach, 1994; Nyberg et al., 1999; Potkin et al., 2003; Miller et al., 2004; Lieberman et al., 2005) , combined with a dose of PIM which saturates brain 5-HT 2A receptors (Nordstrom et al., 2008) receptors (Nordstrom et al., 2008) , while PIM, 5 mg, significantly reduced slow wave sleep in older healthy volunteers (Ancoli-Israel et al., 2011) . The improvement at 6 weeks in the RIS6PBO group was comparable to that in other double-blind, randomized studies of recently hospitalized patients with schizophrenia (Potkin et al., 2003 (Potkin et al., , 2007 . The PANSS and CGI-S data confirm previous reports that RIS 1-2 mg/day is sub-effective for the treatment of chronic schizophrenia (Kapur et al., 2000; Agid et al., 2007) . However, RIS2PIM was superior to RIS2PBO with regard to PANSS total (p = 0.0007), PANSS negative symptoms (p = 0.018), PANSS ≥ 20% (p = 0.001) and ≥50% (p = 0.04) responder rates, and the CGI-S score (p = 0.008) at endpoint. Additionally, discontinuations due to lack of efficacy were notably lower in the RIS2PIM (3.8%) compared to the RIS2PBO group (17.4%) and comparable to that of the RIS6PBO group (4.6%). The results reported here with regard to improvement in negative symptoms are consistent with the benefits reported by Akhondzadeh et al. (2008) from the combination of RIS and ritanserin. The latter results are difficult to interpret because the dose of RIS 6 mg/day would be expected to fully saturate cortical 5-HT 2A receptors (Nyberg et al., 1999) . Ritanserin has moderate potency for 5-HT 2B and 5-HT 2C receptors which might have been spared in the patients treated with risperidone plus placebo (Bonhaus et al., 1995) . The PANSS, but not the CGI-S, data indicated that RIS2PM had a more rapid onset of action than RIS6PBO, whereas no difference in efficacy was evident at week six with either measure. While 63.3% of the subjects in the RIS2PIM group improved in PANSS total by ≥20% by day 15, this response rate was not present in the RIS6PBO group until day 29. The response rate for RIS6PBO at day 15 was not significantly different from that reported in a recent open trial of RIS in schizophrenia patients, in which the mean modal RIS dose was 4.6 mg/day (Kinon et al., 2010) . Altogether, these results suggest that RIS2PIM was at least as effective as RIS6PBO and may have an earlier onset of antipsychotic action.
The HAL treatment results were surprising in that HAL2PBO was as effective as RIS6PBO but as will be explained, the lack of potentiation of HAL by PIM is consistent with clinical and preclinical studies. The 'neuroleptic threshold (NT)' is defined as the threshold dose for EPS and efficacy for typical APDs. For chronic schizophrenia patients, the NT for HAL was reported to be 4.2 ±2.4 mg/day (McEvoy et al., 1986 (McEvoy et al., , 1991 . HAL 2 mg/day is one third the lowest HAL dose (6-15 mg/day) previously used as the active comparator in various randomized controlled trials in schizophrenia (see Hugenholtz et al., 2006) . Clinical trials of patients comparable to those in this study have suggested that a dose of 4 mg/day of HAL is needed to improve psychopathology in most acutely psychotic, non-treatment resistant patients with schizophrenia (McEvoy et al., 1986 (McEvoy et al., , 1991 Zimbroff et al., 1997) . Variations in the type and severity of illness of the patients, and the clinical milieu in which the trials take place, may lead to shifts in the dose-response curve that made these historical benchmarks misleading for the purposes of this study.
We did not observe an efficacy advantage of HAL2PIM over HAL2PBO. However, a significant advantage of HAL2PIM was demonstrated for akathisia. SAS scores (p = 0.07) and ad-hoc BAS scores (p = 0.08) also tended to show an advantage for HAL2PIM over HAL2PBO. The differential effect of PIM to potentiate the efficacy of RIS and not HAL may be related to the recent reports of heterodimers of 5-HT 2A and D 2 receptors and 5-HT 2A and mGluR2 receptors (Fribourg et al., 2011) . Albizu et al. (2011) observed that the effect of HAL to block MK-801 induced increase in locomotor activity models of antipsychotic activity was reduced but not eliminated in 5-HT 2A receptor knock-out mice. We have reported that the ability of sub-effective doses of RIS and other atypical APDs to reverse the deficit in novel object recognition produced by subchronic treatment with the NMDAR antagonist, phencyclidine (PCP) is restored by PIM and M100907, another 5-HT 2A receptor inverse agonist, while HAL, with or without PIM, is ineffective in this regard. We have also reported that the mGlu 2/3 agonist LY379268, did not attenuate the PCP-induced NOR deficit. However, together with sub-effective dose of the atypical APDs, clozapine or lurasidone, whose pharmacology is similar to that of RIS but not HAL or PIM, LY379268 significantly reversed the PCP-induced NOR deficit. Moreover, the effect of clozapine was blocked by the mGlu 2/3 antagonist, LY341495 . The NOR results in this hypoglutamate model of cognitive impairment in schizophrenia are analogous to those found in the current clinical trial and suggest that the hypoglutamate model may better reflect the underlying pathology in patients with schizophrenia than do studies in normal rats, such as those reported by Gardell et al. (2007) in which PIM potentiated the antipsychotic-like actions of HAL. The inability of PIM to potentiate the efficacy of HAL may also be a ceiling effect, or may reflect important differences in the pharmacology of typical and atypical APDs (Meltzer et al., 1989; Meltzer and Huang, 2008) , e.g. the inability of PIM or M100907, another selective 5-HT 2A inverse agonist, to potentiate typical APDs, including HAL and perphenazine, in a rodent cognition model (Snigdha et al., 2010; Meltzer et al., 2011b) . Consideration of plasma levels of HAL and RIS in relation to response in schizophrenia provides another means of assessing whether HAL2mg or RIS2mg would be expected to be sub-effective. Plasma levels of HAL and RIS provide a highly accurate index of D 2 receptor occupancy as measured by PET (Kapur et al., 1996) . HAL 2 mg/day produced D 2 receptor occupancy in the supposedly optimal range of 53-74% in first episode, neuroleptic naïve patients at plasma levels of 1-1.5 ng/ml (Uchida et al., 2011) , whereas plasma levels of 45 ng/ml have been suggested to be necessary for chronic patients (Hugenholtz et al., 2006) . The mean plasma HAL levels in this study ranged from 0.47 to 0.88 ng/ml, well below the levels noted above. These results require replication. If confirmed, they would suggest antipsychotic efficacy may be achieved at lower occupancy of D 2 receptors than previously thought to be necessary. Striatal D 2 receptor occupancy in patients with schizophrenia produced by RIS has been shown to be dose-dependent (Kapur et al., 1995 (Kapur et al., , 1996 (Kapur et al., , 1997 (Kapur et al., , 2000 . RIS 3 mg/day produced 72% mean D 2 receptor occupancy in first episode or neuroleptic-free schizophrenia patients (Nyberg et al., 1999) , leading to the proposal that RIS 4 mg/day is an optimal dose for more chronic patients. While RIS 2 mg/day has been reported to produce a mean 66% D 2 receptor occupancy, which is still believed to be within the optimal range (Kapur et al., 1995) it clearly was a suboptimal dose in this study.
Whether PIM would potentiate the efficacy of a dose of HAL which is sub-effective remains to be determined. What may be concluded from this study is that extensive blockade of 5-HT 2A receptors by PIM does not enhance the efficacy of low dose HAL and that HAL doses as low as 2 mg/day may be sufficient to treat the psychopathology of chronic, as well as first episode schizophrenia patients, experiencing an acute exacerbation. PIM augmentation of HAL2mg did not shorten the time for control of psychopathology, as it did for RIS2mg.
The fact that HAL2PBO and HAL2PIM were as effective as RIS6PBO is consistent with previous reports from this laboratory and others (Lee et al., 1999; Lieberman et al., 2005; Simon et al., 2009 ) that for moderately ill, non-treatment resistant outpatient patients with schizophrenia, there is no difference in improvement in psychopathology between typical APDs and atypical APDS, even clozapine. However, motor side effects from even low doses of typical APDs, will increase the risk for tardive dyskinesia, compared to atypical APDs (Margolese et al., 2005) , providing a strong rationale for preferring treatment with atypical over typical APDs (Meltzer et al., 2010a) .
The more rapid response to RIS2PIM than RIS6PBO is an important finding which has to be confirmed in additional studies. If RIS2PIM is more rapidly effective than higher doses of RIS alone, it might be the result, in part, of lower D 2 receptor occupancy, which, when combined with full 5-HT 2A receptor occupancy achieved by the addition of PIM, can more rapidly produce an optimal restoration of neural activity in the mesolimbic and mesocortical DA systems than is possible in the presence of more extensive occupancy of pre-and postsynaptic D 2 receptors. We have previously reported that additional D 2 receptor blockade, the results of augmentation with RIS 4-6 mg/day, does not improve, and may diminish the efficacy of clozapine, a potent 5-HT 2A receptor antagonist, in treatment resistant patients with schizophrenia (Anil Yagcioglu et al., 2005) . Similar results have been reported by others (Honer et al., 2006) . Full D 2 DA receptor blockade due to the addition of HAL also reduced the efficacy of RIS to restore novel object recognition, a putative measure of declarative memory, in rats treated with subchronic PCP (Snigdha et al., 2010) . It remains to be determined if PIM could also lead to more rapid response to other atypical APDs which share the pharmacology of RIS, e.g. clozapine, lurasidone, olanzapine, etc.
The safety advantages of RIS2PIM over RIS6PBO group were demonstrated in exploratory analyses comparing mean weight gain (p= 0.05), >7% weight gain (p= 0.03), serum prolactin increases (p= 0.0004), serum glucose increases (p = 0.02), and akathisia. There were no meaningful differences between these two treatments in other safety measures. As discussed below, HAL2PIM produced fewer EPS than HAL2PBO. PIM augmentation of sub-effective doses of RIS suggests a new paradigm for utilizing atypical APDs with pharmacology similar to RIS, i.e. the use of lower doses of these drugs, in combination with PIM, to reduce side effects due not only to D 2 receptor occupancy (e.g. EPS and prolactin elevations), but also weight gain, sedation, and blood pressure regulation, related to other dose-dependent receptor interactions. A recent review provided evidence that the metabolic side effects and weight gain associated with clozapine and olanzapine are dose-dependent (Simon et al., 2009) . Potentiation by PIM of the ability of lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone, but not haloperidol, to enhance cortical and hippocampal DA efflux in awake freely moving rats and to enhance the ability of these atypicals to produce acute reversal of the effect of PCP to impair novel object recognition (Snigdha et al., 2010; Horiguchi et al., 2011a Horiguchi et al., , 2011b Meltzer et al., 2011b) supports the possibility that the positive clinical results reported here will extend to other atypical APDs. Undesirable increases in metabolic measures which can contribute to the shorter longevity of patients with schizophrenia and bipolar disorder (Tiihonen et al., 2009 ) might be attenuated with augmentation of sub-effective doses of atypical APDs by 5-HT 2A inverse agonists such as PIM. If the beneficial effects of augmentation with PIM are confirmed by further study, it would favorably impact on the risk-benefit considerations concerning these agents, especially clozapine and olanzapine, which have heavy metabolic burdens at standard doses .
These results further confirm the hypothesis that 5-HT 2A inverse agonism is an important principle in the treatment of psychotic disorders such as schizophrenia (Meltzer et al., 1989 (Meltzer et al., , 2012 Martin et al., 1997; Carlsson et al., 1999) . They are consistent with evidence from PET and post-mortem studies of schizophrenia and controls for non-treatment related alterations in 5HT 2A receptors Erritzoe et al., 2008) genetic studies (Maier et al., 2008) , and animal models of schizophrenia (Meltzer and Huang, 2008; Moreno et al., 2011) for the importance of 5-HT 2A receptors in the etiology and treatment of schizophrenia.
Limitations of this study include the lack of a placebo group. This was not permitted in Brazil. However, the RIS2PBO group served as a pseudo placebo group because it was sub-effective, permitting the recognition of the beneficial effects of augmentation with PIM and facilitating comparison of RIS2PIM with RIS6mg. An additional arm with 20 mg of PIM alone would have provided information on the antipsychotic efficacy of PIM as a standalone agent in acutely psychotic patients with schizophrenia. In addition, using a lower, sub-effective dose of HAL would have tested the hypothesis that PIM could enhance the activity of a sub-effective dose of HAL. We also did not test the ability of PIM to affect cognition, an important issue which deserves further testing.
Conclusion
This study demonstrated that the selective 5-HT 2A inverse agonist, PIM, together with a sub-effective RIS dose, was significantly more efficacious than sub-effective RIS alone and produced fewer side effects than standard dose RIS. PIM did not potentiate HAL2mg, a dose which in this study, at least, was as effective as a standard dose of RIS but it did diminish the akathisia produced by HAL. Potentiation of subeffective doses of RIS, possibly other atypical APDs, and typical APDs with PIM should be further studied as a means of reducing dosedependent side effects and possibly promoting more rapid onset of action with atypical APDs. 
